Full-Time
Posted on 4/11/2026
Pharmaceutical company developing medicines and vaccines
$142.4k - $224.1k/yr
No H1B Sponsorship
North Wales, PA, USA
Hybrid
Hybrid work model: three days on-site per week; Friday remote; days may vary by site.
Bachelor's
See people who can refer or advise you
Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kenilworth, Illinois
Founded
1891
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Hybrid Work Options
Moderna and Merck shares surged Wednesday after reporting positive Phase 3 results for their personalised mRNA cancer vaccine, intismeran autogene, combined with Merck's Keytruda. The trial met its primary endpoint in patients with stage IIB-IV melanoma. This marks the first positive Phase 3 readout for an individualised neoantigen therapy and mRNA-based cancer treatment. Moderna shares more than doubled intraday, whilst Merck jumped over 10%. The vaccine is individually manufactured using mutations from each patient's tumour and encodes up to 34 neoantigens. Earlier Phase 2b data showed the combination reduced recurrence or death risk by 49% compared with Keytruda alone. The companies plan to discuss regulatory submissions with authorities. Nine additional trials are underway across various cancer types, potentially validating Moderna's broader personalised cancer-vaccine platform.
Moderna and Merck announced their personalised melanoma vaccine successfully reduced cancer recurrence in a large late-stage trial. The vaccine, combined with Merck's Keytruda immunotherapy, met its primary goal of reducing melanoma recurrences and slowing the cancer's spread. This marks the first positive final-stage trial for any mRNA-based cancer therapy. Moderna shares more than doubled in pre-market trading, whilst Merck rose as much as 9.5%. The companies will discuss regulatory approval and present detailed data at an upcoming medical meeting. Moderna CEO Stéphane Bancel said the product could be approved as soon as 2027. Melanoma affects roughly 112,000 Americans annually, with about 8,500 deaths per year. The vaccine, called intismeran autogene, is customised based on each patient's specific tumour mutations.
InduPro raises $77M, begins first human trial of cancer drug. by John Cook on Aug 14, 2026 at 6:33 am InduPro, a 4-year-old biotech startup with operations in Seattle and Cambridge, Mass., this week announced $77 million in series B funding as it begins a Phase 1 clinical trial of its lead cancer drug candidate. The company said that the first patient has been dosed in the trial of IDP-001, an experimental antibody-drug conjugate designed to target cancer cells through a combination of two proteins on their surface. The early-stage trial is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors whose disease has progressed following standard treatment. Researchers will evaluate the drug's safety, tolerability, drug behavior and early signs of antitumor activity. InduPro is developing drugs based on the spatial relationships between proteins on the surface of cells. The company says its approach can identify combinations of targets that are close together on cancer cells but not on normal tissue, potentially allowing drugs to more selectively attack tumors. The Series B was led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company. "We are delighted to have the support of this outstanding group of life sciences investors and strategic partners who recognize the potential of our proximity-guided platform to create precision therapeutics in oncology and autoimmune disease," said InduPro CEO Prakash Raman in a press release. Raman is a longtime biopharma executive who previously served as president and CEO of Ribon Therapeutics. Before that, he spent nearly 14 years at Novartis, where he served as vice president and global head of business development and licensing for the Novartis Institutes for Biomedical Research. The company's president and chief scientific officer is Scott Lesley, who previously served as vice president of discovery biologics at Merck. InduPro said the new funding will support the Phase 1 development of IDP-001 and further development of its preclinical pipeline, which includes programs targeting cancer and autoimmune diseases. Earlier this year, InduPro inked a strategic collaboration and licensing agreement with Eli Lilly covering up to three oncology targets, a deal worth up to approximately $950 million.
SCRI and MSD to broaden US oncology trial access. Salong Debbarma Updated Fri, August 14, 2026 at 2:46 AM PDT Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to oncology clinical trials at community sites across the US. The partnership will utilise SCRI's Accelero delivery model, which is designed to improve both the reach and efficiency of cancer studies. MSD and SCRI are seeking to address the increasing complexity of oncology clinical studies, which require more precise patient selection and faster access to new therapies. The organisations aim to implement new approaches for trial delivery that are efficient, use advanced data methods, and can be integrated within local communities. MSD Research Laboratories associate vice-president and North America global clinical trial operations head Jennifer Coppola said: "At MSD, we are focused on advancing research to better understand cancer and potential therapeutic approaches. "By leveraging the Accelero delivery model, we have the potential to reach patients faster, reduce protocol complexity, and make oncology clinical studies more accessible in the communities where patients live." The Accelero model employed by SCRI includes accelerated trial site start-up, electronic data transfer systems connecting electronic health records (EHR) and case report forms, and initiatives to boost recruitment. Collaborations using Accelero have reported trial site activations up to 50% faster than conventional approaches, with enrolment rates 19% higher than the national average of 7%, and 95% fewer changes to data compared to standard processes. SCRI runs a network comprising around 1,500 oncology physicians, offering access to clinical studies at over 200 sites in more than 20 US states. The group reports involvement in over 900 first-in-human clinical trials since its formation. In October 2024, Exelixis and MSD partnered to assess the potential of combining their respective cancer therapies in upcoming trials. "SCRI and MSD to broaden US oncology trial access" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Merck reported second-quarter revenue of $16.61 billion, beating analyst estimates of $16.27 billion with 5.1% year-on-year growth. The pharmaceutical company's performance was driven by strong sales of KEYTRUDA in oncology and robust Animal Health results. The company raised its full-year revenue guidance to $66.8 billion at the midpoint but lowered adjusted earnings per share guidance to $2.71, a 46.9% decrease. Operating margin fell to -3.5% from 31.6% in the prior year, affected by higher operating expenses and acquisition-related charges. During the earnings call, analysts questioned management about planned clinical trials for pembrolizumab in first-line lung cancer, TL1A activity compared to TNF inhibitors, and commercial adoption expectations for LIPFENDRA. CEO Robert Davis highlighted expansion opportunities for oral PCSK9 treatments in primary care markets.